Novo Nordisk appoints ex-Pfizer head
pharmafile | May 10, 2012 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Novo Nordisk, Pfizer, Robert Clark, regulatory affairs
Robert Clark will be joining Novo Nordisk as vice president, regulatory affairs.
Clark will lead Novo Nordisk’s US regulatory team, and maintain relationships with key individuals and agencies outside of Novo Nordisk that play a specific role in the FDA’s review and approval process.
“Bob is bringing 27 years of experience and knowledge of the global and US regulatory environment, and it’s that know-how we require for an increasingly complex pharmaceutical marketplace,” said Anne Philips, corporate vice president, Clinical Development, Medical and Regulatory Affairs.
Clark comes to Novo Nordisk from Pfizer, where he was US Regulatory Strategy Head. During his time at Pfizer, he led or supported approvals of new medicines in cardiovascular, endocrine, women’s health and anti-infective therapy areas. Additionally, he is an expert on US pharmaceutical advertising and promotional practices.
Related Content
Pfizer shares update on DMD gene therapy clinical trial
Pfizer has announced an update from its phase 3 randomised, multicentre, double-blind, placebo-controlled CIFFREO trial, …
NHS accepts Pfizer’s tafamidis for ATTR-CM treatment
NHS England has announced that it has accepted Pfizer’s drug, tafamidis, for the treatment of …
Pfizer’s Beqvez approved by FDA for haemophilia B treatment
Pfizer has announced that the US Food and Drug Administration (FDA) has approved Beqvez (fidanacogene …